Search Results - "Mullooly, M."

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells by Caiazza, F, McGowan, P M, Mullooly, M, Murray, A, Synnott, N, O'Donovan, N, Flanagan, L, Tape, C J, Murphy, G, Crown, J, Duffy, M J

“…Background: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen…”
Get full text

ADAM-17: a novel therapeutic target for triple negative breast cancer by McGowan, P.M., Mullooly, M., Caiazza, F., Sukor, S., Madden, S.F., Maguire, A.A., Pierce, A., McDermott, E.W., Crown, J., O'Donovan, N., Duffy, M.J.

“…Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2…”
Get full text

Ductal carcinoma in situ (DCIS) and breast cancer-specific and all-cause mortality among postmenopausal women in the Women’s Health Initiative by Pan, K., Nelson, R., Mullooly, M., Simon, M., Mortimer, J., Rohan, T., Wactawski-Wende, J., Lane, D., Manson, J., Chlebowski, R., Kruper, L.

Get full text

558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer by Mullooly, M, O'Brien, N, Finn, R.S, Slamon, D.J, Crown, J, McGowan, P.M, Duffy, M.J

Get full text

129 ADAM17: A new therapeutic target for triple negative breast cancer? by McGowan, P, Mullooly, M, Sukor, S, O'Donovan, N, Duffy, M.J

Get full text

Impacts of the COVID-19 pandemic on the breast cancer control pathway in Ireland by Tierney, P A, McDevitt, J, Brennan, A, Zhang, M, Mullooly, M, Bennett, K, Walsh, P M, Murray, D

Get full text

1730P Dealing with digital paralysis: Surviving a cyberattack in a cancer centre by Keogh, R.J., Harvey, H.M., Brady, C., Hassett, E., Costelloe, S.J., O’Sullivan, M.J., Twomey, M., O'Leary, M.J., Cahill, M.R., O'Riordan, A., Joyce, C.M., Flavin, A., Bambury, R., Murray, D., Bennett, K., Mullooly, M., O'Reilly, S.

Get full text

P136 - Ductal carcinoma in situ (DCIS) and breast cancer-specific and all-cause mortality among postmenopausal women in the Women’s Health Initiative by Pan, K., Nelson, R., Mullooly, M., Simon, M., Mortimer, J., Rohan, T., Wactawski-Wende, J., Lane, D., Manson, J., Chlebowski, R., Kruper, L.

Get full text

Abstract P5-12-01: Adjuvant endocrine therapy and risk of contralateral breast cancer among a cohort of U.S. women with breast cancer by Gierach, GL, Curtis, RE, Pfeiffer, RM, Mullooly, M, Hoover, RN, Nyante, SJ, Feigelson, HS, Glass, AG, Berrington de Gonzalez, A

“…Background: The increasing incidence of estrogen receptor (ER)-positive breast cancer in the U.S. in concert with the aging population and improved survival…”
Get full text

Dihematoporphyrin ether-induced photosensitivity in laryngeal papilloma patients by Mullooly, V M, Abramson, A L, Shikowitz, M J

“…Twenty-six patients with recurrent laryngeal papillomatosis received 2.5 mg/kg of Dihematoporphyrin Ether (DHE) intravenously prior to photodynamic therapy…”
Get more information

Clinical exacerbation of systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis by Abramson, A L, Alvi, A, Mullooly, V M

“…Photodynamic therapy was used to treat a patient with recurrent laryngotracheal papillomatosis who had a history of systemic lupus erythematosus (SLE). At the…”
Get more information

ADAMs as new therapeutic targets for triple-negative breast cancer by Mullooly, M., McGowan, P. M., Sukor, S. U., Madden, S. F., McDermott, E., Crown, J., O'Donovan, N., Duffy, M. J.

“…Abstract only…”
Get full text

P3-17-03: ADAM17: A Novel Therapeutic Target for Treatment of Triple Negative Breast Cancer by McGowan, PM, Mullooly, M, Sukor, S, Madden, S, McDermott, E, Pierce, A, Crown, J, O'Donovan, N, Duffy, MJ

“…Background: Due to the absence of ER, PR and HER2, targeted therapy is currently unavailable for patients with triple negative breast cancer (TNBC). Although…”
Get full text

Clinical effects of alpha-interferon dose variation on laryngeal papillomas by Mullooly, V M, Abramson, A L, Steinberg, B M, Horowitz, M S

“…Achieving optimal clinical control of recurrent respiratory papillomatosis with prolonged treatment with human leukocyte (alpha) interferon appears to be…”
Get more information

Clinical effects of photodynamic therapy on recurrent laryngeal papillomas by Abramson, A L, Shikowitz, M J, Mullooly, V M, Steinberg, B M, Amella, C A, Rothstein, H R

“…Thirty-three patients with moderate to severe recurrent laryngeal papillomatosis underwent photodynamic therapy at our institution. All received 2.5 mg/kg of…”
Get more information

Variable light-dose effect on photodynamic therapy for laryngeal papillomas by Abramson, A L, Shikowitz, M J, Mullooly, V M, Steinberg, B M, Hyman, R B

“…We investigated photodynamic therapy (PDT) as an alternative treatment modality for recurrent respiratory papillomatosis. To optimize the effect of PDT, the…”
Get more information

ADAM-17: a novel therapeutic target for triple negative breast cancer by McGowan, P M, Mullooly, M, Caiazza, F, Sukor, S, Madden, S F, Maguire, A A, Pierce, A, McDermott, E W, Crown, J, O'Donovan, N, Duffy, M J

“…Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2…”
Get full text

Music for postoperative pain and anxiety by Mullooly, V M, Levin, R F, Feldman, H R

Get more information